

Medicaid Pharmacy Drug Utilization Review (DUR) Program Update

Effective April 12, 2012, the fee-for-service pharmacy program will implement the following parameters which include step therapy and frequency/quantity/duration (F/Q/D) requirements. These changes are the result of recommendations made by the Drug Utilization Review Board (DURB) at the March 8, 2012, DURB meeting.

Angiotensin Converting Enzyme Inhibitors (ACEI)/Angiotension Receptor Blockers (ARB)/Direct Renin Inhibitors (DRI) and Related Combination Products:

- ▶ Require trial with a product containing an ACEI prior to initiating a preferred ARB
- ▶ Require trial with a product containing either an ACEI or an ARB prior to initiating a preferred DRI

Amitiza:

- ▶ Require trials of both a bulking-agent and an osmotic laxative prior (defined as within 89 days) to lubiprostone
- ▶ Duration limit of 30 days with 2 refills per prescription

Selective Serotonin Reuptake Inhibitors/Serotonin-Norepinephrine Reuptake Inhibitors:

- ▶ Require trial with an SSRI prior to an SNRI (exception for specific indications: Chronic musculoskeletal pain (CMP), Diabetic peripheral neuropathy (DPN) and Fibromyalgia (FM))

Human Growth Hormone (HGH)

- ▶ Require diagnosis for all HGH products regardless of patient age

With the implementation of new system enhancements, prescribers can prevent the need to obtain certain prior authorizations (PA) by properly coding all medical claims with the appropriate diagnoses and following clinical recommendations.

DURB recommendations for step therapy and FQD are based on best practice, as established by FDA approved manufacturer labeling, official compendia, and major treatment guidelines. Recommendations are instituted to ensure clinically appropriate and cost effective use of these drugs and drug classes. To view all DURB recommendations visit the DUR program web site at:

http://www.health.ny.gov/health_care/medicaid/program/dur/index.htm

The Preferred Drug List also includes links to the DUR program web site for drugs/drug classes within the Preferred Drug Program that are affected by step therapy and F/Q/D requirements. The most recent PDL can be found at: <https://newyork.fhsc.com/>